Neoadjuvant Opdivo with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial Pharmaceutical Investing
BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created "SpinCo" Entity whereby Shareholders to Receive One New Share of "SpinCo" in Addition to Each Current Share of BriaCell Already Held Pharmaceutical Investing
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27 Life Science Investing
FDA Converts to Full Approval Indication for KEYTRUDA® for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors Life Science Investing
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023 Pharmaceutical Investing
BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article Pharmaceutical Investing
Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human Trials Pharmaceutical Investing
Bristol Myers Squibb Receives European Commission Approval of Sotyktu , a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis Pharmaceutical Investing
KEYTRUDA® Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status Life Science Investing
Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity Pharmaceutical Investing
